AMBICION
Tokyo
About AMBICION
AMBICION specializes in developing cancer immunotherapies targeting Natural Killer T cells. The company is advancing a proprietary pipeline, including RK-pulsed autologous and allogeneic antigen-presenting cells, to address unmet medical needs in oncology. It collaborates with renowned research institutions and aims to establish standard treatments for cancer patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.3M
- Last round: Series Unknown (Apr 2018)
- Website: ambicion.co.jp
- Phone: +81 3-5357-7231
Industries & Categories
Biotechnology, Health Care, Medical, Nursing and Residential Care, Product Research
Canonical: https://fsome.com/organization/ambicion-143124 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.